Guardian Pharmacy Services, Inc.

NYSE•GRDN

CEO: Mr. Fred P. Burke

セクター: Healthcare

業種: Medical - Distribution

上場日: 2016-04-21

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

連絡先情報

300 Galleria Parkway SE, Suite 800, Atlanta, GA, 30339, United States

404-810-0089

guardianpharmacy.com

時価総額

$2.38B

PER (TTM)

48.3

30.2

配当利回り

52週高値

$41.36

52週安値

$19.17

52週レンジ

83%

順位30Top 19.5%

5.1

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

堅調 • 5.1 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q4 2025 データ

売上高

$397.62M+0.00%

直近4四半期の推移

EPS

$0.33+0.00%

直近4四半期の推移

フリーCF

$30.37M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth Strong Revenue reached $1.45B USD in 2025, marking a 17.9% increase over 2024 results, driven by organic growth.

Operating Income Turnaround Switched to $72.7M USD operating income in 2025 from prior year loss of $62.9M K, showing profitability.

Adjusted EBITDA Improvement Adjusted EBITDA reached $115.1M USD, showing strong growth of 26.8% compared to the previous year's $90.8M K.

High ALF Adoption Rate Resident adoption rate reached 89% at ALFs served by year-end December 31, 2025, demonstrating key operational strength.

リスク要因

Intense Market Competition Competition from national/local pharmacies may erode profit margins and adversely affect operating results and cash flow.

Healthcare Cost Pressures Continuing government efforts to lower drug prices via reforms like IRA may adversely impact profitability and reimbursement rates.

Labor Shortages Harm Growth Inability to attract/retain pharmacists and staff could harm growth strategy implementation and increase operating costs.

Cybersecurity Incident Risk Past ransomware attack highlights risk; future security incidents could disrupt operations and expose us to regulatory penalties.

見通し

Growth Strategy Pillars Core strategy centers on organic growth via new residents and increased adoption, supplemented by strategic M&A activity.

Technology Investment Focus Continued investment in automation, data analytics (Guardian Compass/Shield), and IT infrastructure planned for efficiency gains.

Ongoing Geographic Expansion Expansion through acquiring compatible pharmacies or developing greenfield start-ups in existing and underserved regional markets.

New Predictive Programs Actively developing new predictive tools, including Falls Risk Management and Disease State Management services for LTCFs.

同業比較

売上高 (TTM)

QDEL

$2.73B

-1.9%

TDOC

$2.53B

-1.5%

$1.91B

-4.9%

粗利益率 (最新四半期)

NUVB

99.0%

+182.9pp

NVCR

75.8%

-3.9pp

STAA

73.4%

+17.6pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
EWTX	$3.69B	-21.1	-32.0%	0.7%
TWST	$3.67B	-47.7	-16.6%	28.8%
TXG	$3.33B	-76.1	-5.7%	15.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

6.5%

安定成長

4四半期純利益CAGR

30.3%

収益性の大幅な改善

キャッシュフロー安定性

100%

優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年5月6日

EPS:$0.24

売上高:$330.19M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし